{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:16:45Z","timestamp":1790367405644,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","plasticsurgery.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Plastic Surgery"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cps.2017.02.016","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T01:19:27Z","timestamp":1496279967000},"page":"583-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Robert","family":"Cartotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cps.2017.02.016_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.cps.2017.02.016_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A\u00a0multicenter review of Toxic Epidermal Necrolysis treated in US burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.cps.2017.02.016_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson Syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"S3","key":"10.1016\/j.cps.2017.02.016_bib5","first-page":"S3","article-title":"Epidermal necrolysis in association with mycoplasma pneumonia infection","volume":"126","author":"Grosber","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The Euro-SCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.cps.2017.02.016_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.cps.2017.02.016_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.cps.2017.02.016_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"10.1016\/j.cps.2017.02.016_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2012.04.002","article-title":"Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"66","author":"Chung","year":"2012","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.cps.2017.02.016_bib12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"New Engl J Med"},{"issue":"90","key":"10.1016\/j.cps.2017.02.016_bib13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.cps.2017.02.016_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen specific immune receptors: the p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.cps.2017.02.016_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.cps.2017.02.016_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.cps.2017.02.016_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cps.2017.02.016_bib18","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.4049\/jimmunol.162.12.7140","article-title":"Crosstalk between keratinocytes and T lymphocytes via Fas\/Fas ligand interaction: modulation by cytokines","volume":"162","author":"Arnold","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cps.2017.02.016_bib19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2011.09.029","article-title":"Toxic epidermal necrolysis: review of pathogenesis and\u00a0management","volume":"66","author":"Downey","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.cps.2017.02.016_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CCM.0b013e31829eb94f","article-title":"Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation","volume":"42","author":"deProst","year":"2014","journal-title":"Crit Care Med"},{"issue":"968","key":"10.1016\/j.cps.2017.02.016_bib21","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/pgmj.2005.042952","article-title":"Colonic involvement in Stevens Johnson syndrome","volume":"82","author":"Powell","year":"2006","journal-title":"Postgrad Med J"},{"issue":"6","key":"10.1016\/j.cps.2017.02.016_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000195632","article-title":"Acute renal failure and its risk factors in Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"29","author":"Hung","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cps.2017.02.016_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0738-081X(98)00011-X","article-title":"Drug-induced toxic epidermal necrolysis","volume":"16","author":"Wolkenstein","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A\u00a010 year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.cps.2017.02.016_bib25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to a regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.cps.2017.02.016_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cps.2017.02.016_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1529-8019.2011.01396.x","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis: a review of treatment options","volume":"24","author":"Worswick","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.cps.2017.02.016_bib28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.cps.2017.02.016_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/BCR.0b013e3181cb8cb8","article-title":"What are the fluid requirements in toxic epidermal necrolysis?","volume":"31","author":"Shiga","year":"2010","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.cps.2017.02.016_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","article-title":"A\u00a0multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care TrialsGroup","volume":"340","author":"Hebert","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cps.2017.02.016_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0884533608323434","article-title":"Energy requirements of pediatric patients with Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"23","author":"Mayes","year":"2008","journal-title":"Nutr Clin Prac"},{"key":"10.1016\/j.cps.2017.02.016_bib32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.1987.03390160057026","article-title":"Toxic epidermal necrolysis: a step forward in treatment","volume":"257","author":"Heimbach","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.cps.2017.02.016_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archsurg.1984.01390170097019","article-title":"Improved treatment of the Stevens-Johnson syndrome","volume":"119","author":"Marvin","year":"1984","journal-title":"Arch Surg"},{"key":"10.1016\/j.cps.2017.02.016_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00004630-198103000-00006","article-title":"Human cadaver homograft in toxic epidermal necrolysis","volume":"2","author":"Davidson","year":"1981","journal-title":"J\u00a0Burn Care Rehabil"},{"issue":"3","key":"10.1016\/j.cps.2017.02.016_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004630-199005000-00010","article-title":"Biobrane\u00ae wound dressing used in the treatment of toxic epidermal necrolysis: a case report","volume":"11","author":"Sowder","year":"1990","journal-title":"J\u00a0Burn Care Rehabil"},{"issue":"11","key":"10.1016\/j.cps.2017.02.016_bib36","first-page":"1477","article-title":"Toxic epidermal necrolysis: a burn-centre challenge","volume":"144","author":"Peters","year":"1991","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.cps.2017.02.016_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000637-199508000-00002","article-title":"Toxic epidermal necrolysis: a review and report of the successful use of Biobrane\u00ae for early wound coverage","volume":"35","author":"Bradley","year":"1995","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.cps.2017.02.016_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in survivors of toxic epidermal necrolysis treated in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.cps.2017.02.016_bib39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.burns.2014.02.006","article-title":"A\u00a0systematic review of toxic epidermal necrolysis treated in burns centres","volume":"40","author":"Mahar","year":"2014","journal-title":"Burns"},{"key":"10.1016\/j.cps.2017.02.016_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.cps.2017.02.016_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane\u00ae or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.cps.2017.02.016_bib42","first-page":"S122","article-title":"The use of a temporary biosynthetic skin substitute in Stevens-Johnson-Toxic Epidermal Necrolysis Syndrome","volume":"37","author":"Rogers","year":"2016","journal-title":"J\u00a0Burn Care Res"},{"issue":"12","key":"10.1016\/j.cps.2017.02.016_bib43","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.cps.2017.02.016_bib44","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in\u00a0toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cps.2017.02.016_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.cps.2017.02.016_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.cps.2017.02.016_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study of patients included in the prospective Euro-SCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.cps.2017.02.016_bib49","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.eye.6701653","article-title":"High dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits","volume":"19","author":"Yip","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.cps.2017.02.016_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high dose intravenous immunoglobulin and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1016\/j.cps.2017.02.016_bib51","first-page":"119","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: 11 years experience and outcome","volume":"11","author":"Gravante","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cps.2017.02.016_bib52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome and toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib54","first-page":"e121","article-title":"A\u00a0systematic review of drug induced Stevens Johnson syndrome and toxic epidermal necrolysis in children","volume":"18","author":"Del Pozzo-Magana","year":"2011","journal-title":"J\u00a0Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.cps.2017.02.016_bib55","first-page":"473","article-title":"Treatment of toxic epidermal necrolysis with cyclosporine A.","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"J\u00a0Trauma"},{"key":"10.1016\/j.cps.2017.02.016_bib56","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib57","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.cps.2017.02.016_bib58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cps.2017.02.016_bib59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity of illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib61","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during thefirst five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.cps.2017.02.016_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a Burn Center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J\u00a0Burn Care Res"},{"issue":"4","key":"10.1016\/j.cps.2017.02.016_bib63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2010.04.026","article-title":"Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN","volume":"150","author":"Morales","year":"2010","journal-title":"Am J Ophthal"}],"container-title":["Clinics in Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094129817300317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094129817300317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T21:13:35Z","timestamp":1692825215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094129817300317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0094129817300317"],"URL":"https:\/\/doi.org\/10.1016\/j.cps.2017.02.016","relation":{},"ISSN":["0094-1298"],"issn-type":[{"value":"0094-1298","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Plastic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cps.2017.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}